References
- Heise T, Korsatko S, Nosek L, et al. Steady state is reached within two to three days of once-daily administration of degludec, a basal insulin with an ultra-long duration of action. J Diabetes 2015; published online 12 January 2015, doi: 10.1111/1753-0407.12266
- Heise T, Nosek L, Bottcher SG, et al. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012;14:944-50
- Korsatko S, Deller S, Koehler G, et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Clin Drug Investig 2013;33:515-21
- Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012;14:859-64
- Heller S, Buse J, Fisher M, et al. BEGIN Basal–Bolus Type 1 Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal–bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal–Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379:1489-97
- Bode BW, Buse JB, Fisher M, et al.; BEGIN Basal–Bolus Type 1 trial investigators. Insulin degludec improves glycemic control with lower nocturnal hypoglycemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN Basal–Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med 2013;30:1293-7
- Evans M, McEwan P, Foos V. Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice – a case-based evaluation. J Med Econ 2015;18:96-105
- Evans M, Wolden M, Gundgaard J, et al. Cost-effectiveness of insulin degludec compared with insulin glargine in a basal–bolus regimen in patients with type 1 diabetes mellitus in the UK. J Med Econ 2015;18:56-68
- Hollander P, Cooper J, Bregnhøj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008;30:1976-87
- Raskin P, Gylvin T, Weng W, Chaykin L. Comparison of insulin detemir and insulin glargine using a basal–bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev 2009;25:542-8
- Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetologia 2008;51:408-16
- Devries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev 2007;23:441-54
- Meneghini L, Kesavadev J, Demissie M, et al. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Diabetes Obes Metab 2013;15:729-36
- King AB. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study. Diabetes Obes Metab 2009;11:69-71
- King AB. No higher dose requirements with insulin detemir than glargine in type 2 diabetes: a crossover, double-blind, and randomized study using continuous glucose monitoring. J Diabetes Sci Technol 2010;4:151-4
- Jakobsen M, Dalsgaard M, Hørmann M, Møller DV. Insulin analogues dosing and costs – comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients. BMC Endocr Disord 2012;12:21